Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 28 | 2025Regeneron and Novartis Q3 ‘25 Earnings; More Novo Leadership Changes Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Oct 27 | 2025Lilly Taps Shaq for OSA Awareness; Biomea Doses First Patient with Oral GLP-1RA; Fibronostics Acquisition for MASH Diagnostics Purchase Blast
$599
Posted in: Other, Topics Oct 24 | 2025Sanofi Q3 ‘25 Earnings; Novo Initiates Ph3 Cagrilintide ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 23 | 2025Roche and Viking Q3 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 23 | 2025Terns Discontinues Obesity Program; Lingo Available at Walmart; Roche Partners For CVRM Manufacturing; Biocon Expands US Glargine Partnership; NewAmsterdam Registers Ph3 Study of Obicetrapib FDC and MonotherapyPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Oct 21 | 2025Novo Board Updates; Viking Ph1 Maintenance StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 20 | 2025Rybelsus CVRR Approval; FDA Hands Out First CNPVs, Including Tzield; Novo Hires New SVP; Ascletis Ph2 ASC30 Trial Update; BI Appoints New Obesity and Liver Head Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Oct 16 | 2025Lilly Ph3 Orfor T2DM Results; Abbott Q3 ’25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 15 | 2025Obesity Spotlight: How Will Lilly Maintain Market Leadership?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Oct 14 | 2025Kailera Raises $600M for its Ph3 Obesity ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Oct 14 | 2025Novo Cuts Cell Therapy R&D Division; FDA Accepts Afrezza Peds sBLA; Ascletis Selects Obesity Candidate; Lilly Initiates Ph2 Macupatide and Eloralintide Trial; October CHMP Agenda Purchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Oct 10 | 2025Ypsomed Builds US Manufacturing Site; Eccogene Eyes Hong Kong IPO; Former Novo CEO Joins Healthcare DenmarkPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 09 | 2025Novo Acquires Akero for EFX in MASHPurchase Blast
$599
Posted in: Dual/triple agonist, Insulin Delivery, Other, Topics Oct 07 | 2025Biomea Ph2 T2DM Results; AZ Ph3 Baxdrostat Data; Ionis 2025 Innovation Day; New Hanmi Ph2 Triple Agonist Study; MannKind Completes scPharmaceuticals Acquisition; Fractyl Health Preclinical Gene Therapy Data Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Oct 07 | 2025Ed Cinca Rejoins Novo as SVP of US Marketing; Skye’s CB1 Ph2a Dose Suboptimal; Amgen Launches its DTP Program; Wegovy Pill Available DTP via Telehealth; Costco Sells Ozempic and Wegovy; Libre Featured on ESPN; Lilly Partners with Local Manufacturers in IndiaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 02 | 2025New Orforglipron SUI Trial; Amgen VESALIUS-CV Results; EASO Recommends GLP-1RAsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 01 | 2025Alnylam/Roche Initiate Zilebesiran CVOT; Hanmi Files Obesity IND; Sagimet Ph1 MASH StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 30 | 2025Metsera Ph2b VESPER Results; NovoCare Partners with LifeMD; Novo Terminates CV Partnership; MindRank Ph1b Obesity Results; Cascade Initiates Ph2 MASH StudyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 29 | 2025Novo Resubmits Icodec BLA; BI and Novartis Launch DTP Platforms; t:slim X2 + Control-IQ+ Now Compatible with LyumjevPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other, SGLT2i, Topics Sep 26 | 2025AZ Launches DTP Platform; Biolinq Shine Receives De Novo Classification; Amgen Expands US Manufacturing; Fractyl REMAIN-1 Results; Sanofi Expands Insulin SavingsPurchase Blast